Get the Stockscreener App
49.32
0.99%
-0.38
Supernus Pharmaceuticals Inc stock is traded at $49.32, with a volume of 117.16K.
It is down -0.99% in the last 24 hours and up +11.53% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$49.70
Open:
$49.7
24h Volume:
117.16K
Relative Volume:
0.15
Market Cap:
$2.83B
Revenue:
$665.13M
Net Income/Loss:
$64.50M
P/E Ratio:
43.10
EPS:
1.1442
Net Cash Flow:
$185.87M
1W Performance:
-4.58%
1M Performance:
+11.53%
6M Performance:
+53.44%
1Y Performance:
+35.07%
1-Day Range:
$48.70
$50.05
1-Week Range:
$48.70
$51.75
52-Week Range:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
49.32 | 2.85B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
ZTS
Zoetis Inc
|
125.41 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.48 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus Pharmaceuticals Earnings Notes - Trefis
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
SUPN (Supernus Pharmaceuticals) EV-to-OCF : 37.98 (As of Dec. 25, 2025) - GuruFocus
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing - marketscreener.com
Supernus Pharmaceuticals Senior VP Sells Shares - TradingView — Track All Markets
Supernus Pharmaceuticals (SUPN) Is Up 6.0% After FDA Approval Of ONAPGO Parkinson’s DrugHas The Bull Case Changed? - Sahm
Will Supernus Pharmaceuticals Inc. stock deliver long term returnsEarnings Growth Summary & Daily Profit Maximizing Trade Tips - DonanımHaber
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Stifel raises Supernus Pharmaceuticals stock price target to $55 from $50 - Investing.com Canada
How Supernus Pharmaceuticals Inc. stock performs after earningsPortfolio Risk Report & Long Hold Capital Preservation Tips - Bölüm Sonu Canavarı
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 - Finviz
Why retail investors pile into Supernus Pharmaceuticals Inc. stock2025 Breakouts & Breakdowns & Smart Investment Allocation Tips - DonanımHaber
Why The OLB Group, Inc. stock attracts strong analyst attention - DonanımHaber
How risky is Supernus Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - Улправда
Is Supernus Pharmaceuticals Inc. stock overvalued by current metrics2025 Market Outlook & AI Driven Price Predictions - Улправда
Has the Market Fully Recognized Supernus Pharmaceuticals’ Strong Run and Growth Prospects in 2025? - Yahoo Finance
Supernus Pharmaceuticals (SUPN): Assessing Valuation After a 33% One-Year Return and Undervalued Narrative - Yahoo Finance
SUPN to Participate in Cantor Fitzgerald Virtual Meeting - GuruFocus
Supernus Pharmaceuticals (SUPN): Assessing Valuation After Recent CNS Portfolio Progress and ONAPGO Approval - Sahm
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - Yahoo Finance
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - The Motley Fool
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - MSN
(SUPN) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Supernus Pharmaceuticals Reports Strong Q3 2025 Growth - MSN
Supernus Pharmaceuticals Says Postpartum Depression Treatment Receives Authorization From Health Canada - marketscreener.com
Can Supernus Pharmaceuticals Inc. stock resist market sell offsRate Hike & Scalable Portfolio Growth Ideas - Newser
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Responsive Playbooks and the SUPN Inflection - news.stocktradersdaily.com
Supernus Pharmaceuticals Inc Stock Analysis and ForecastMerger & Acquisition Updates & Buy Sell Signal Notifications - earlytimes.in
Reversal Confirmed Inter Globe Finance Limited Stock Rallies Above MAStock Price Forecasts & High Return Capital Gain - earlytimes.in
Supernus Pharmaceuticals (SUPN) Is Down 17.4% After Raising 2025 Guidance Amid Margin and Supply Pressures – Has the Bull Case Changed? - Sahm
Is Supernus Pharmaceuticals Inc a good long term investmentChart Pattern Recognition & Small Budget Trading Portfolio - earlytimes.in
What analysts say about Supernus Pharmaceuticals Inc stockEconomic Data Impact & Outstanding Return Stocks - earlytimes.in
SUPN insider Form 4 shows 15,000-share option exercise at $12.98 - Stock Titan
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 - Yahoo Finance
Healthcare Stocks Analysis 2025: COO & SUPN to Sell, HCA to BuyNews and Statistics - IndexBox
Assessing Supernus Pharmaceuticals (SUPN) Valuation as Shares Hold Steady Following Period of Range-Bound Trading - Sahm
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
How Supernus Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Supernus (Nasdaq: SUPN) to join Piper Sandler 37th Conference fireside chat Dec. 2 - Stock Titan
Supernus to acquire depression drugmaker Sage - MSN
Why Supernus Pharmaceuticals Inc. stock could benefit from AI revolutionQuarterly Trade Summary & Growth Focused Entry Point Reports - newser.com
Understanding the Setup: (SUPN) and Scalable Risk - news.stocktradersdaily.com
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Sale |
50.41 |
20,000 |
1,008,150 |
15,496 |
1.43%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):